Interferon-β treatment reduced the percentages of CD86 positive (+) cells and C-C chemokine receptor type 5 (CCR5)+ cells within the naive B cell subset in MS patients, providing less co-stimulatory signals and rendering them less motile [66]. Here, CCR5 is linked to myeloid sarcoma.